Outcome of the Meeting of the Board of Directors of the Company held on August 04, 2026, is attached.

Ref: AHCL/2026-27/C031 August 04, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot No C/1, G Block, Dalal Street, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 001 Mumbai – 400 051 Scrip Code – 544350 Symbol : AGARWALEYE Dear Sir / Madam, Sub: Outcome of the Board Meeting held on August 04, 2026 Ref: Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) Pursuant to the captioned subject, reference and in continuation of our letter dated July 28, 2026, we wish to inform that, the Board of Directors of the Company at its meeting held today, i.e., Tuesday, August 04, 2026, has, inter alia, considered and approved the following: A. Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter ended June 30, 2026 Pursuant to Regulation 33 of the SEBI Listing Regulations, the Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter ended June 30, 2026, along with the Limited Review Report issued by M/s. S.R. Batliboi & Associates LLP, Chartered Accountants, the Statutory Auditors of the Company and the Press Release are enclosed herewith. Further, the aforesaid Financial Results shall be published in the newspapers in compliance with Regulation 47 of the SEBI Listing Regulations and be made available on the website of the Company at www.dragarwals.co.in B. Appointment of M/s. S.R. Batliboi & Associates LLP, Chartered Accountants, as the Statutory Auditors, to hold office as such, until the conclusion of the 20th Annual General Meeting (AGM) of the Company This is with reference to our earlier letters dated November 12, 2025, & December 19, 2025, intimating the appointment of M/s. S.R. Batliboi & Associates LLP, Chartered Accountants, (Firm Registration No: 101049W/E300004) as the Statutory Auditors of the Company to hold office as such until the conclusion of the ensuing 16th AGM of the company, for the purpose of filling the casual vacancy arising from the resignation of M/s. Deloitte Haskins & Sells, Chartered Accountants, the erstwhile Statutory Auditors of the Company, during the financial year 2025-26. Based on the recommendations of the Audit Committee, it was proposed to appoint M/s. S.R. Batliboi & Associates LLP, Chartered Accountants, as the Statutory Auditors of the Company, to hold office as such w.e.f. the conclusion of the ensuing 16th AGM until the conclusion of the 20th AGM of the Company, subject to the approval of the Members of the Company. C. Appointment of M/s. KPMG Assurance and Consulting Services LLP, as the Internal Auditors of the Company for the financial year 2026-27 In accordance with the provisions of Section 138 of the Companies Act, 2013, read with the rules made thereunder and as recommended by the Audit Committee, M/s. KPMG Assurance and Consulting Services LLP, were appointed as the Internal Auditors to conduct the internal audit functions and activities of the Company for the financial year 2026-27. D. Re-appointment of M/s. B Y & Associates, Practicing Cost Accountants, as the Cost Auditors of the Company for the financial year 2026-27 In accordance with the provisions of Section 148 of the Companies Act, 2013, read with the Companies (Cost Records and Audit) Rules, 2014, and as recommended by the Audit Committee, M/s. B Y & Associates, Practicing Cost Accountants, (Firm Registration No. 003498) were re-appointed as the Cost Auditors to conduct the audit of the Cost Records of the Company for the financial year 2026-27. E. Incorporation of a Wholly Owned Subsidiary in Nigeria Orbit Healthcare Services (Mauritius) Limited, a direct wholly owned subsidiary of the Company, has proposed to incorporate a wholly owned subsidiary in Nigeria. Post which, the newly incorporated Nigerian entity shall become a step-down / indirect wholly owned subsidiary of the Company. The proposed incorporation shall be subject to the receipt of all necessary regulatory, statutory, and governmental approvals and permissions as may be required under the applicable laws of Nigeria and Mauritius. The details as required under Regulation 30 read with Schedule III of the SEBI Listing Regulations and the SEBI master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, regarding the aforesaid appointment, re-appointment of Auditors and Incorporation of Wholly Owned Subsidiary, are enclosed herewith as Annexure I, II, III and IV respectively. The meeting commenced at 11:50 A.M. IST and concluded at 01:45 P.M. IST We request you to kindly take the above on record. For Dr. Agarwal’s Health Care Limited Thanikainathan Arumugam Company Secretary and Compliance Officer Encl.: as above. Press Release August 04, 2026 DR. AGARWAL’S HEALTH CARE LIMITED Q1 FY2027 Revenue from Operation grows by 26.0% YoY to ₹614 Crores Q1 FY2027 Total Income grows by 23.9% YoY to ₹620 Crores Q1 FY2027 IND-AS EBITDA grows by 25.2% YoY to ₹177 Crores Q1 FY2027 PAT grows by 44.6% YoY to ₹55 Crores Chennai, August 04, 2026: Dr. Agarwal’s Health Care Limited (NSE: AGARWALEYE, BSE: 544350), India’s largest eye care service chain(1) operating a network of 304 Facilities across 10 countries, today announced its unaudited consolidated financial results for the quarter ended June 30, 2026 Highlights of the Quarter Ended June 30, 2026 (Q1 FY2027) - As of June 30, 2026, our network stands at 304 facilities, with 18 new facilities added during the quarter comprising of 1 Tertiary, 15 Secondary and 2 Primary facilities o Commissioned 16 new surgical facilities – the highest ever in a single quarter - Performed 91,082 surgeries in Q1 FY2027, growth of 15.5% YoY - Total Income of INR 620 Crores; growth of 23.9% YoY - Revenue from Operations of ₹614 Cr; growth of 26.0% YoY o Revenue from Operations – India of ₹552 Cr, growth of 25.3% YoY o Revenue from Mature Facilities of ₹485 Cr, growth of 37.1% YoY o Sale of Services(2) contributed 77.7% and Sale of Products(2) contributed 22.3% to revenue from operations - EBITDA of ₹177 Cr, growth of 25.2% YoY with EBITDA margins of 28.5% - Profit after Tax of ₹55 Cr, growth of 44.6% YoY with profit after tax margins of 8.9% Commenting on the stellar performance for Q1 FY2027, Dr. Adil Agarwal, CEO, Dr. Agarwal’s Health Care Limited, said: “This has been an exceptional quarter for us on multiple fronts. We delivered our highest ever sequential quarter-on-quarter revenue growth, underscoring the strong momentum across our business. We also set a new record with the launch of 16 greenfield surgical facilities in a single quarter — the highest ever in our history. Revenue from operations for the quarter stood at ₹614 crore, a growth of 26.0% over the same period last year, driven by healthy growth across all of our regions. Our EBITDA rose by 25.2% to ₹177 crore, underscoring our focus on operational efficiency and cost discipline despite rising greenfield losses driven by 23 surgical facilities launched in the last six months. Profit after tax rose to ₹55 crore, up 44.6% year-on-year. Operationally, our network grew to 304 eye care facilities as of June 30, 2026, with 18 new additions during the quarter. We served over 8.8 lakh+ patients and performed c.91,000+ surgeries, supported by our team of 1,050+ doctors. Q1 FY27 witnessed a record addition of 16 surgical facilities, delivering nearly half of FY26's total surgical facility additions in a single quarter. Our greenfield execution engine is firing, and with a strong pipeline already in place, we remain confident of delivering on the full-year plan.” (1) By revenue from operations for Q1 FY27 (2) Services include Surgeries, Consultation, Treatments and Investigations; Products include Opticals, Contact Lens and Accessories, and Pharmaceutical Products; Excludes other operating revenue Consolidated Performance Highlights: Quarter Ended (In INR C [Showing first 8,000 characters — download PDF for full document]